Image provided by BioHarvest
A new clinical trial of Vinia, a red grape powder product from BioHarvest (Rehovot, Israel), suggests it may offer benefits to patients with type 2 diabetes. The study results will soon be published in a peer-reviewed journal, according to BioHarvest.
“The preliminary results of this study show that moderate doses of Vinia may positively affect patients with type 2 diabetes,” said Yochi Hagay, PhD, CEO for BioHarvest. “This is a promising result for people with type 2 diabetes or those at high risk for developing this condition.”
Vinia contains 40mg of polyphenols, including 5 mg of resveratrol sourced solely from red grape as piceid (reservatrol glycosides). The soon-to-be-published study included 33 adults who consumed Vinia daily for twelve weeks and were evaluated for diabetic paramaters as well as clock gene expression.
Malkit Azachi, PhD, vice president of R&D at BioHarvest confirmed that the preliminary results of the study are “extremely encouraging,” and said BioHarvest is already looking toward future studies.
“These results still need to be confirmed in a larger patient population,” said Azachi. “We are encouraged by these findings and plan to conduct additional studies to further explore the potential utility of Vinia in improving glucose metabolism.”
Nutritional Outlook Magazine